How This Works
Bremelanotide (PT-141) is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), acting as a non-selective melanocortin receptor agonist with predominant activity at MC3R and MC4R. In the central nervous system, MC4R activation leads to enhanced dopamine release in key brain reward and arousal regions—including the nucleus accumbens and medial preoptic area—which increases sexual motivation and desire. Unlike PDE5 inhibitors (e.g., sildenafil), PT-141 does not directly affect the nitric oxide pathway; in males, its pro-erectile effect is secondary to central mechanisms stimulating nitric oxide production in penile tissue. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation.
Potential Benefits & Side Effects
Observations from clinical literature.
Benefits: Clinical trials in premenopausal women with HSDD showed PT-141 significantly improves sexual desire scores (FSFI-Desire) and reduces distress (FSDS-DAO) versus placebo.
Early studies in men demonstrated improved erectile responses with intranasal PT-141.
Common Side Effects: Nausea (~40%), flushing (~20%), headache (~11%); these are typically mild and transient.
Other Effects: Transient blood pressure elevation, skin hyperpigmentation with repeated use.
Subcutaneous administration provides ~100% bioavailability and is better tolerated than intranasal delivery.
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.